MR
MacLeod Roderick H. Chief Financial Officer
Other M
Insider track record CFO Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Discover the full record of transactions filed by MacLeod Roderick H., Chief Financial Officer. Director active across 1 company, notably NEVRO CORP. In total, 27 filings have been recorded. History available since 15 June 2021. The latest transaction was filed on 20 March 2025 (Attribution). Regulator: SEC (Form 4). The full history is openly available.
Declarations 27 total
● SVP, Chief Financial Officer · Executives · 3 Apr 2025 · NEVRO CORP 350,663 shares Common Stock SEC:0000950170-25-050471:0
◆ SVP, Chief Financial Officer · Executives · 20 Mar 2025 · NEVRO CORP 1,136 shares 0Common Stock SEC:0001444380-25-000050:0
● SVP, Chief Financial Officer · Executives · 7 Mar 2025 · NEVRO CORP 1,763 shares @ US$5.77 1.1% of flow Common Stock SEC:0001444380-25-000037:0
◆ SVP, Chief Financial Officer · Executives · 28 Feb 2025 · NEVRO CORP 742 shares 0Common Stock SEC:0001444380-25-000030:0
● SVP, Chief Financial Officer · Executives · 7 Dec 2024 · NEVRO CORP 1,759 shares @ US$4.19 0.8% of flow Common Stock SEC:0001444380-24-000016:0
● SVP, Chief Financial Officer · Executives · 28 Nov 2024 · NEVRO CORP 816 shares @ US$4.58 0.4% of flow Common Stock SEC:0001444380-24-000008:0
● SVP, Chief Financial Officer · Executives · 7 Sept 2024 · NEVRO CORP 1,759 shares @ US$5.18 0.9% of flow Common Stock SEC:0001610717-24-000471:0
● SVP, Chief Financial Officer · Executives · 28 Aug 2024 · NEVRO CORP 817 shares @ US$5.76 0.5% of flow Common Stock SEC:0001610717-24-000458:0
● SVP, Chief Financial Officer · Executives · 15 Jun 2024 · NEVRO CORP 1,619 shares @ US$9.03 1.6% of flow Common Stock SEC:0001610717-24-000346:0
● SVP, Chief Financial Officer · Executives · 7 Jun 2024 · NEVRO CORP 1,759 shares @ US$9.27 1.7% of flow Common Stock SEC:0001610717-24-000322:0
● SVP, Chief Financial Officer · Executives · 28 May 2024 · NEVRO CORP 816 shares @ US$9.52 0.8% of flow Common Stock SEC:0001610717-24-000270:0
◆ Chief Financial Officer · Executives · 7 Mar 2024 · NEVRO CORP 84,326 shares 0Common Stock SEC:0001610717-24-000145:0
◆ Chief Financial Officer · Executives · 4 Mar 2024 · NEVRO CORP 743 shares 0Common Stock SEC:0001610717-24-000138:0
● Chief Financial Officer · Executives · 2 Mar 2024 · NEVRO CORP 1,270 shares @ US$14.22 1.9% of flow Common Stock SEC:0001610717-24-000126:0
● Chief Financial Officer · Executives · 28 Feb 2024 · NEVRO CORP 898 shares @ US$14.82 1.4% of flow Common Stock SEC:0001610717-24-000105:0
● Chief Financial Officer · Executives · 28 Nov 2023 · NEVRO CORP 800 shares @ US$16.67 1.4% of flow Common Stock SEC:0001610717-23-000370:0
● Chief Financial Officer · Executives · 28 Aug 2023 · NEVRO CORP 800 shares @ US$19.39 1.7% of flow Common Stock SEC:0001610717-23-000248:0
● Chief Financial Officer · Executives · 15 Jun 2023 · NEVRO CORP 1,585 shares @ US$24.97 4.2% of flow Common Stock SEC:0001610717-23-000190:0
● Chief Financial Officer · Executives · 28 May 2023 · NEVRO CORP 800 shares @ US$26.45 2.3% of flow Common Stock SEC:0001610717-23-000084:0
◆ Chief Financial Officer · Executives · 7 Mar 2023 · NEVRO CORP 39,282 shares 0Common Stock SEC:0001567619-23-004746:0
● Chief Financial Officer · Executives · 2 Mar 2023 · NEVRO CORP 1,133 shares @ US$33.99 4.2% of flow Common Stock SEC:0001567619-23-004532:0
● Chief Financial Officer · Executives · 28 Feb 2023 · NEVRO CORP 3,352 shares @ US$31.44 11.4% of flow Common Stock SEC:0001567619-23-004207:0
● Chief Financial Officer · Executives · 15 Jun 2022 · NEVRO CORP 1,579 shares @ US$42.25 11.5% of flow Common Stock SEC:0001567619-22-013132:0
● Chief Financial Officer · Executives · 2 Mar 2022 · NEVRO CORP 1,186 shares @ US$71.27 13.7% of flow Common Stock SEC:0001567619-22-006436:0
◆ Chief Financial Officer · Executives · 28 Feb 2022 · NEVRO CORP 18,249 shares 0Common Stock SEC:0001567619-22-006145:0
25 of 27 declarations
Load more (2 remaining) About MacLeod Roderick H. Roderick H. MacLeod is Chief Financial Officer of Nevro Corp. In this role, he oversees the financial management of the company, including financial planning and regulatory compliance. Roderick brings valuable expertise in finance, thereby contributing to the financial strategy of Nevro. His commitment to financial transparency is essential for the company.